Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

NCT Number	NCT05269394
Lead Sponsor	Washington University School of Medicine Collaborators: Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Conditions	Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Enrollment	197 participants
Start Date	2021-12-22
Primary Completion	2028-04 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-13